XTLB
XTL Biopharmaceuticals Ltd. Sponsored ADR · NASDAQ
- Sector Health Technology
- Industry Medical Specialties
- Website xtlbio.com
- Employees(FY) -
- ISIN US98386D3070
Performance
-20.44%
1W
-18.64%
1M
-40.5%
3M
-41.94%
6M
+42.56%
YTD
+41.84%
1Y
Profile
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Technical Analysis of XTLB 2024-12-20
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-08-13 21:15
- 2024-06-16 19:40
- 2024-06-04 21:15
XTL Entered Definitive Agreement to Acquire The Social Proxy(Globenewswire)
- 2024-05-12 19:23
- 2024-04-28 19:33
- 2024-03-19 22:15
XTL To Aquire The Social Proxy(Globenewswire)
- 2023-10-20 04:00
- 2023-10-20 04:00
- 2018-11-20 19:00
- 2018-10-31 22:09
- 2018-07-23 21:09
- 2018-05-29 05:37
- 2017-12-12 18:30
- 2017-12-05 23:08
- 2017-11-26 21:30
- 2017-10-22 23:23
- 2017-10-05 19:30
- 2017-10-04 19:50
- 2017-09-25 21:23
- 2017-09-11 21:00
- 2017-07-10 19:00
- 2017-06-14 21:00
- 2017-04-26 21:50
- 2017-04-04 21:10
- 2017-03-29 20:55
- 2017-03-21 21:22
- 2017-03-06 23:40
- 2017-02-28 19:30
- 2017-02-16 19:00
- 2017-02-12 20:08
Page 1 of 3
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.